San Francisco Department of Public Health, 25 Van Ness Ave Suite 500, San Francisco, CA 94102, United States; University of California San Francisco, 1825 4th St, San Francisco, CA 94158, United States.
University of California San Francisco, 1825 4th St, San Francisco, CA 94158, United States.
Drug Alcohol Depend. 2022 Jul 1;236:109478. doi: 10.1016/j.drugalcdep.2022.109478. Epub 2022 Apr 29.
Fentanyl has replaced most other non-prescribed opioids in much of North America. There is controversy over whether a hypothetical reduced efficacy of naloxone in reversing fentanyl is a major contributor to the coincident rising overdose mortality.
We modified an existing Markov decision analytic model of heroin overdose and naloxone distribution to account for known risks of fentanyl by adjusting overdose risk, the likelihood of death in the event of overdose, and the proportion of cases in which available naloxone was administered in time to prevent death. We assumed near-universal survival when naloxone was administered promptly for heroin or fentanyl overdose, but allowed that to decline in sensitivity analyses for fentanyl. We varied the proportion of use that was fentanyl and adjusted the modified parameters accordingly to estimate mortality as the dominant opioid shifted.
Absent naloxone, the annual overdose death rate was 1.0% and 4.1% for heroin and fentanyl, respectively. With naloxone reaching 80% of those at risk, the overdose death rate was 0.7% and 3.6% for heroin and fentanyl, respectively, representing reductions of 26.4% and 12.0%. Monte Carlo simulations resulted in overdose mortality with fentanyl of 3.3-5.2% without naloxone and 2.6-4.9% with naloxone, with 95% certainty. Positing reduced efficacy for naloxone in reversing fentanyl resulted in 3.6% of fentanyl overdose deaths being prevented by naloxone.
Heightened risk for overdose and subsequent death, alongside the time-sensitive need for naloxone administration, fully account for increased mortality when fentanyl replaces heroin, assuming optimal pharmacologic efficacy of naloxone.
芬太尼已在北美的大部分地区取代了大多数其他非处方类阿片类药物。关于纳洛酮逆转芬太尼作用假设效力降低是否是导致同时上升的过量死亡率的主要因素存在争议。
我们修改了现有的海洛因过量和纳洛酮分布的马尔可夫决策分析模型,通过调整过量风险、过量情况下死亡的可能性以及及时给予可用纳洛酮以防止死亡的情况下的病例比例,来考虑芬太尼已知的风险。我们假设在及时给予纳洛酮治疗海洛因或芬太尼过量时,几乎可以完全存活,但在芬太尼的敏感性分析中允许这种情况的可能性下降。我们改变了芬太尼的使用比例,并相应调整修改后的参数,以估计随着主要阿片类药物的转变,死亡率会如何变化。
在没有纳洛酮的情况下,海洛因和芬太尼的年过量死亡率分别为 1.0%和 4.1%。当纳洛酮到达 80%的风险人群时,海洛因和芬太尼的过量死亡率分别为 0.7%和 3.6%,分别降低了 26.4%和 12.0%。蒙特卡罗模拟结果显示,在没有纳洛酮的情况下,芬太尼的过量死亡率为 3.3-5.2%,而有纳洛酮的情况下为 2.6-4.9%,95%置信区间。假设纳洛酮逆转芬太尼的效力降低,将有 3.6%的芬太尼过量死亡可被纳洛酮预防。
当芬太尼取代海洛因时,由于过量和随后死亡的风险增加,以及纳洛酮给药的时间敏感性需求,假设纳洛酮的药效最佳,完全可以解释死亡率的上升。